Exicure to Present at 2019 BIO Investor Forum
October 21 2019 - 4:32PM
Business Wire
Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and
immunotherapeutic drugs utilizing spherical nucleic acid (SNA™)
constructs, announced today that its chief financial officer, David
Snyder, will give a company update on Tuesday, October 22, 2019 at
11:00am PT at the 2019 BIO Investor Forum in San Francisco.
A live audio webcast will be available on the Investors section
of Exicure’s website: www.exicuretx.com. The webcast will be
archived for approximately 30 days following the event.
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company
developing therapeutics for immuno-oncology, inflammatory diseases
and genetic disorders based on our proprietary Spherical Nucleic
Acid, or SNA technology. Exicure believes that its proprietary SNA
architecture has distinct chemical and biological properties that
may provide advantages over other nucleic acid therapeutics and may
have therapeutic potential to target diseases not typically
addressed with other nucleic acid therapeutics. Exicure's lead
program is in a Phase 1b/2 trial in patients with advanced solid
tumors. Exicure is based outside of Chicago, IL and in Cambridge,
MA.www.exicuretx.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191021005819/en/
MacDougall Karen Sharma 781-235-3060 ksharma@macbiocom.com
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jul 2023 to Jul 2024